<DOC>
	<DOCNO>NCT01989078</DOCNO>
	<brief_summary>Sickle cell nephropathy ( SCN ) progressive complication sickle cell disease ( SCD ) begin childhood result renal ( kidney ) failure early mortality nearly 12 % adult hemoglobin SS ( HbSS ) . The potential prevention reversal kidney damage SCD know . Albuminuria commonly use biomarker glomerular damage ; however correlation albuminuria specific measurement glomerular function pathophysiology determine . The investigator hypothesize patient persistent albuminuria despite treatment SCD hydroxyurea , losartan reverse kidney dysfunction early stage nephropathy ameliorate progressive kidney dysfunction advance nephropathy . The primary aim study acute longer-term effect losartan ( study drug ) specific glomerular function child adult SCD persistent albuminuria . Research glomerular function test do study entry ( prior take losartan ) , 1 month , 1 2 year start losartan therapy ( participant may take losartan 24 month ) . In addition , participant see month clinic assess regular clinical team . The second aim ass correlation change albuminuria 1 month losartan change direct measurement glomerular function 12-24 month , thus determine magnitude initial decrease albuminuria response losartan predicts sustain improvement renal function .</brief_summary>
	<brief_title>Losartan Sickle Cell Kidney Disease</brief_title>
	<detailed_description>Sickle cell nephropathy ( SCN ) progressive complication sickle cell disease ( SCD ) begin childhood result renal ( kidney ) failure early mortality nearly 12 % adult hemoglobin SS ( HbSS ) . The potential prevention reversal kidney damage SCD know . Albuminuria commonly use biomarker glomerular damage ; however correlation albuminuria specific measurement glomerular function pathophysiology determine . The investigator hypothesize patient persistent albuminuria despite treatment SCD hydroxyurea , losartan reverse kidney dysfunction early stage nephropathy ameliorate progressive kidney dysfunction advance nephropathy . Losartan FDA-approved drug treat blood pressure protect kidney people disease like diabetes blood pressure . It specifically label use sickle cell disease . Participants enrol Children 's Healthcare Atlanta ( pediatric subject ) Grady Memorial Hospital ( adult subject ) study 1 2 year ( depend final renal function test preform ) . The primary aim pilot study evaluate acute longer-term effect losartan ( study drug ) renal function child adult SCD persistent albuminuria . The renal function test do study entry ( prior take losartan ) , 1 month , 1 2 year start losartan therapy . In addition , participant assess monthly regular clinical team . The second aim study assess correlation change albuminuria 1 month losartan change direct measurement renal function 12-24 month , thus determine magnitude initial decrease albuminuria response losartan predicts sustain improvement renal function .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>SCD genotype HbSS HbS/beta0thalassemia Age great equal 9 year old Urinary albumin/creatinine ratio ( ACR ) great equal 30 mg/gram creatinine great equal 2 occasion separate one month Current treatment hydroxyurea sustain hematologic response 6 month prior enrollment Endstage renal failure ( estimate GFR &lt; 30 ml/min/1.73 m2 ) Known coexistent medical condition could affect kidney , diabetes mellitus , systemic lupus erythematosus ( SLE ) , human immunodeficiency virus ( HIV ) positive Chronic therapy ( daily use â‰¥8 week ) nonsteroidal antiinflammatory drug ( NSAIDs ) Females pregnant Preexisting hyperkalemia ( serum potassium &gt; 5.5 milliequivalent per liter ( mEq/L ) ) Current chronic transfusion therapy</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Kidney disorder</keyword>
	<keyword>Blood disorder</keyword>
	<keyword>Pediatrics</keyword>
</DOC>